Vivos (RDGL) Total Current Liabilities

: $0.25 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Vivos's total current liabilities for the quarter that ended in Dec. 2023 was $0.25

Vivos Total Current Liabilities Historical Data

The historical data trend for Vivos's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Annual Data

Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23

Total Current Liabilities

1.52 0.91 0.17 0.08 0.25

Vivos Quarterly Data

Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23

Total Current Liabilities 0.08 0.05 0.11 0.11 0.25

Vivos Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Vivos's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 0.245 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 0 + 0

= 0.25

Vivos's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 0.245 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 0 + 0

= 0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Vivos Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Vivos's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivos (RDGL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » Total Current Liabilities

Comparable Companies

CUTR NMTC SNWV IINN MOVE MDAI CODX AXDX NSYS ECOR TSE:5212 ABT SYK MDT BSX EW DXCM SZSE:300760 ZBH ALGN

Traded in Other Exchanges

N/A

Address

719 Jadwin Avenue, Richland, WA, USA, 99352

Website

https://www.radiogel.com

Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.

Executives

Michael K Korenko officer: INTERIM CEO AND PRESIDENT 6208 W OKANOGAN AVE, KENNEWICK WA 99336

Michael H Pollack officer: Interim CFO 114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036

Memorial Institute Battelle 10 percent owner 505 KING AVENUE, COLUMBUS OH 43201

Kenin M. Spivak director 9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210

Thomas J Clement director 12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034

Leonard Bruce Jolliff officer: Chief Financial Officer 206 N 41ST ST., UNIT 1, YAKIMA WA 98901

Cadwell Family Irrevocable Trust 10 percent owner 909 NORTH KELLOGG STREET, KENNEWICK WA 99336

James C Katzaroff director, 10 percent owner, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352

Bruce Wayne Ratchford director, 10 percent owner 6208 W. OKANOGAN AVE., KENNEWICK WA 99336

Carlton M Cadwell director, 10 percent owner 6208 W OKANOGAN AVE, KENNEWICK WA 99336

Vivos (RDGL) Headlines

From GuruFocus

Vivos Inc Successfully Treats Canine Sarcoma with IsoPet™ (RadioGel™)
By Marketwired Marketwired • 05-31-2018

Vivos Inc. Provides Intellectual Property Protection Update
By GuruFocusNews GuruFocusNews • 06-01-2022

Vivos Inc Obtains Trademark Protection for IsoPet®
By Marketwired Marketwired • 07-30-2018

Vivos Inc Signs a Standstill Agreement with Debt Holders Designed to Halt the Toxic Selling and Create a Debt Free Company
By Marketwired Marketwired • 09-22-2018

Vivos Inc. Files Early Feasibility IDE Application with FDA for Radiogel�
By Marketwired Marketwired • 09-20-2021

Vivos Inc Retains Well-Know OTC Markets Analyst, George Sharp, as Advisor
By Marketwired Marketwired • 09-25-2018

Vivos Inc Initiates Isopet� Therapy in Horses
By Marketwired Marketwired • 06-24-2021

Vivos Inc Obtains Feedback from the FDA on Clinical Testing of RadioGel�
By GuruFocusNews GuruFocusNews • 12-02-2021

Vivos Inc. Enhances its Intellectual Property Protection
By GuruFocusNews GuruFocusNews • 02-24-2022

Vivos Inc. Provides Intellectual Property Protection Update
By GuruFocusNews GuruFocusNews • 05-12-2022

Vivos Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Liabilities																0.08	0.05	0.11	0.11	0.25

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	0.245	+	0
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	0	+	0
	=	0.25

Michael K Korenko	officer: INTERIM CEO AND PRESIDENT	6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack	officer: Interim CFO	114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle	10 percent owner	505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak	director	9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement	director	12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff	officer: Chief Financial Officer	206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust	10 percent owner	909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff	director, 10 percent owner, officer: CEO	719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford	director, 10 percent owner	6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell	director, 10 percent owner	6208 W OKANOGAN AVE, KENNEWICK WA 99336